Seeking Novel Drug Candidates and Targets for Cardiovascular Disorders

CSL is interested in research developing novel therapeutic candidates or exploring novel drug targets for cardiovascular disease, with a particular focus on rare cardiovascular diseases. CSL has a high interest in engaging with academic research focusing on biologics as well as cell and gene therapies (including gene editing), with a particular interest in plasma-derived protein therapeutics.

Areas of Particular Interest

- Rare Lipid Disorders
- Myocarditis
- Animal Models of Myocarditis
- Familial Cardiomyopathies
- Refractory Angina

Development Stage

- Opportunities at the levels of basic through to late pre-clinical research
- Targets validated by patient data, biomarker identification and/or animal models would be advantageous

Submission Information

One-page research summaries are encouraged, plus any relevant non-confidential supporting documents

Out of scope

- Opportunities in clinical stages are not of interest
- Small molecule approaches are not within scope, with RNA approaches being of low interest

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spin-out companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 19th October 2020 - 10:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

CSL develops and delivers biotherapies for people with life-threatening medical conditions. CSL's broad range of therapies include those to treat disorders such as haemophilia and primary immune deficiencies.